U.S. Markets closed

Pharmaxis Ltd (PXSLY)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
3.01+0.44 (+17.12%)
At close: 9:49AM EDT
People also watch
QRXPYCLVLYPOLXFNVDLPRTX

Pharmaxis Ltd

20 Rodborough Road
Frenchs Forest, NSW 2086
Australia
61 2 9454 7200
http://www.pharmaxis.com.au

Sector
Industry
Full Time Employees62

Key Executives

NameTitlePayExercisedAge
Mr. Gary Jonathan Phillips BPharm, MBACEO & DirectorN/AN/A56
Mr. David Morris McGarvey BA, CA, CPACFO & Company Sec.N/AN/A61
Mr. Wolfgang G. Jarolimek B.Sc. Ph.D.Head of Drug DiscoveryN/AN/A53
Dr. Brett Charlton MBBS Ph.D.Medical DirectorN/AN/A61
Ms. Kristen Morgan BSc,PGDipBusAdmin,MMedScExec. Officer157.43kN/A45
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Pharmaxis Ltd engages in the research, development, and commercialization of human healthcare products for the treatment and management of chronic diseases worldwide. The company operates through two segments, Bronchitol and Aridol Business, and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, a lung function test used to help doctors in diagnosing and managing asthma by detecting active airway inflammation through measuring airway hyper-responsiveness. The company’s amine oxidase drug development programs include selective LOXL2 inhibitor for pulmonary fibrosis, non-alcoholic steatohepatitis, and liver and kidney fibrosis; mixed LOXL/LOXL2 inhibitor for cancer, severe liver and kidney fibrosis, and tissue scarring; semicarbazide-sensitive amine oxidase (SSAO)/MAO-B inhibitor for neuro inflammation; and SSAO/MPO inhibitor for lung inflammation, asthma, and chronic obstructive pulmonary disease. It has a research collaboration with Woolcock Institute of Medical Research to develop a novel inhalation therapy for the treatment of cystic fibrosis. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.

Corporate Governance

Pharmaxis Ltd’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.